Alder Hey Children's Hospital, Liverpool, UK.
Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Eur J Hosp Pharm. 2020 Mar;27(2):60-64. doi: 10.1136/ejhpharm-2018-001805. Epub 2019 Jan 28.
Quinolone antibiotics have a broad spectrum of activity including against Gram-negative organisms (especially ), but their use has been associated with the development of seizures. Our objective was to evaluate the association between the administration of quinolones and seizures for three groups of children: those with epilepsy; those with other CNS disorders; and those without any CNS disorder.
We conducted a systematic review of the MEDLINE, EMBASE and CENTRAL databases. Any studies reporting the administration of quinolones to children and including a methodology for identifying or reporting adverse events were identified by two authors who worked independently. Data relating to study characteristics (including population, intervention, comparison and outcome data) and study quality (including the quality of adverse event reporting) were extracted.
We identified 140 studies involving 21 884 children. No studies reported involving children with epilepsy and 21 studies reported the involvement of 317 children with CNS disorders. 2/317 (0.63%) children with CNS disorders developed seizures and at least 4/21 567 (0.023%) children without CNS pathology were reported to have developed seizures. The quality of adverse event reporting in included studies was low. Only 8/140 (5.71%) included studies provided details of a methodology for actively identifying adverse neurological events.
Even for children with CNS disorders the risk of developing seizures in association with the use of quinolones seems to be low. Further evaluations of quinolone use in children should include methodologies for actively identifying and reporting adverse neurological events.
喹诺酮类抗生素具有广谱的活性,包括对革兰氏阴性菌(尤其是 ),但其使用与癫痫发作的发展有关。我们的目的是评估喹诺酮类药物与三组儿童癫痫发作的关系:患有癫痫的儿童;有其他中枢神经系统疾病的儿童;以及无任何中枢神经系统疾病的儿童。
我们对 MEDLINE、EMBASE 和 CENTRAL 数据库进行了系统评价。两名独立工作的作者确定了报告给儿童使用喹诺酮类药物并包括识别或报告不良事件方法学的任何研究。提取了与研究特征(包括人群、干预、比较和结局数据)和研究质量(包括不良事件报告的质量)相关的数据。
我们确定了 140 项涉及 21884 名儿童的研究。没有研究报告涉及癫痫儿童,21 项研究报告了 317 名中枢神经系统疾病儿童的参与情况。317 名中枢神经系统疾病儿童中有 2/317(0.63%)发生了癫痫发作,至少有 4/21567 名无中枢神经系统疾病的儿童报告发生了癫痫发作。纳入研究中不良事件报告的质量较低。仅 8/140(5.71%)纳入研究提供了主动识别不良神经事件方法学的详细信息。
即使对于患有中枢神经系统疾病的儿童,使用喹诺酮类药物引起癫痫发作的风险似乎也很低。进一步评估儿童使用喹诺酮类药物应包括主动识别和报告不良神经事件的方法学。